The following table provides an overview of the latest patents of Innate Pharma that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3405495Feb 24, 2021Neutralization Of Inhibitory Pathways In Lymphocytes1
EP3191517Nov 4, 2020Cross Reactive Siglec Antibodies1